

## Measures 1-3 are collaborative wide

## The target must be achieved at the state level in <u>2 of 3</u> measures to receive reimbursement.

\*Measure #4 provides an opportunity to receive VBR for attending MSTCVS meetings.

Sites are eligible for VBR reimbursement if the targets are achieved at the site level in all four measures.

	Statewide Measure Description	Measurement Period	Baseline State Mean	Statewide Target Performance
1	Invasive mediastinal staging for patients undergoing lung cancer resection (Clinical IB or greater, lobectomy, segmentectomy and pneumonectomy)	Jan-Sept 2023	63%	66%
2	Pathologic sampling of 3 mediastinal and 1 hilar lymph node station at the time of lung cancer resection (Lobectomy, segmentectomy and pneumonectomy)	Jan-Sept 2023	75%	80%
3	Time from diagnosis to lung cancer resection (Percentage of lung cancer patients with a date of CT scan and date of surgeon consult recorded)	Jan-Sept 2023	NA	80%
4	Surgeon and Data Manager participation in quarterly Collaborative meetings *site-specific opportunity	Jan-Sept 2023	NA	*2 out of 3 meetings (February/April/August)

## 2023 MSTCVS VALUE-BASED REIMBURSEMENT TOBACCO CESSATION MEASURE

## Tobacco cessation treatment or counseling referral for current smokers

- Patients will receive at least one of the following:
  - 1) pharmacologic cessation treatment
  - 2) Referral to an inpatient/outpatient counseling program,
  - 3) Referral to 1-800-Quit-Now

	Measure Description	Measurement Period	Baseline State Mean	Hospital-Level Target Performance
	Adult Cardiac	Jan 1, 2023 – Sept 30, 2023	44%	100%
1	General Thoracic	Jan 1, 2023 – Sept 30, 2023	64%	100%